PANACRO
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PANACRO - overview
Established
2004
Location
Hefei, Anhui, China
Primary Industry
Pharmaceuticals
About
Founded in 2004 and based in Beijing, China, PANACRO is a medical services company that focuses on pharmaceutical R&D and clinical research CRO services. It was recognized as a National High-tech enterprise. Min Zhao, the CEO and the founder of the company, used to work in clinical research at the Boehringer Ingelheim Medical Registry. The company has four subsidiaries in Suzhou and other cities.
In December 2023, PANACRO raised a series B1 funding for approximately CNY 100 million. The company's main business is to provide services related to clinical research and registration filing for chemical drugs, biological drugs, and vaccines. Its services include Phase I-IV clinical trials, data management, statistical analysis for pharmaceutical product development, and other related services. Its service clients include Guangzhou Phar.
Holdings, NEPTUNUS, Henlius, and other enterprises. The company will use the funding for the advancement of internationalization and digital intelligence business, as well as the expansion of the North American and Southeast Asian markets.
Current Investors
CoStone Capital, Jinyuan Kuntong Equity Investment Management, Topsailing Capital
Primary Industry
Pharmaceuticals
Sub Industries
Business Support Services, Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.panacro.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.